| dc.contributor.author | Coşkun D. | |
| dc.contributor.author | Aytaç J. | |
| dc.date.accessioned | 2019-08-13T12:10:23Z | |
| dc.date.accessioned | 2019-08-13T15:53:42Z | |
| dc.date.available | 2019-08-13T12:10:23Z | |
| dc.date.available | 2019-08-13T15:53:42Z | |
| dc.date.issued | 2006 | |
| dc.identifier.issn | 0899823X | |
| dc.identifier.uri | https://dx.doi.org/10.1086/507969 | |
| dc.identifier.uri | http://hdl.handle.net/11446/2005 | |
| dc.description | PubMed ID: 17006823 | en_US |
| dc.description.abstract | We evaluated changes in the rate of healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA) infections and healthcare-associated S. aureus infections after implementation of infection control precautions and the effect of this on glycopeptide use and expenditures for glycopeptides in a private medical center in Turkey in the years 2000-2005. A striking decrease was obtained in the number of MRSA infections, and the expenditure for glycopeptide use also decreased. © 2006 by The Society for Healthcare Epidemiology of America. All rights reserved. | en_US |
| dc.language.iso | eng | en_US |
| dc.identifier.doi | 10.1086/507969 | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | The decrease in healthcare-associated methicillin-resistant Staphylococcus aureus infections and savings from glycopeptide use | en_US |
| dc.type | article | en_US |
| dc.relation.journal | Infection Control and Hospital Epidemiology | en_US |
| dc.department | DBÜ | en_US |
| dc.identifier.issue | 10 | en_US |
| dc.identifier.volume | 27 | en_US |
| dc.identifier.startpage | 1131 | en_US |
| dc.identifier.endpage | 1132 | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.department-temp | DBÜ | en_US |
